Whitehawk Therapeutics (WHWK) Gross Margin (2021 - 2025)
Whitehawk Therapeutics (WHWK) posted quarterly Gross Margin of 89.36% for Q1 2025, up 154.0% year-over-year from 35.18% in Q1 2024, and little changed quarter-over-quarter from 89.09% in Q4 2024.
Whitehawk Therapeutics (WHWK) Gross Margin (2021 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Gross Margin for 5 consecutive years, with 89.36% the latest figure, recorded in Q1 2025.
- In Q1 2025, Gross Margin rose 154.0% year-over-year to 89.36%; the TTM figure through Dec 2025 stood at 89.36% (up 100.0% YoY), while the FY2025 annual figure was 89.36%, up 100.0% from the prior year.
- Gross Margin was little changed at 89.36% in Q1 2025 per WHWK's latest filing, from 89.09% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q4 2021 and bottomed at 85.35% in Q4 2023.
- Historically, Gross Margin has averaged 90.05% across 5 years, with a median of 89.23% in 2024.
- Annual changes were most pronounced in 2023 — Gross Margin sank 1041 bps — and 2024, when it soared 374 bps.
- Whitehawk Therapeutics' Gross Margin stood at 100.0% in 2021, then decreased by 4 bps to 95.75% in 2022, then fell by 11 bps to 85.35% in 2023, then rose by 4 bps to 89.09% in 2024, then climbed by 0 bps to 89.36% in 2025.
- Business Quant data shows WHWK's Gross Margin at 89.36% in Q1 2025, 89.09% in Q4 2024, and 88.85% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 89.36% |
| Dec 31, 2024 | 89.09% |
| Sep 30, 2024 | 88.85% |
| Jun 30, 2024 | 87.41% |
| Mar 31, 2024 | 87.82% |
| Dec 31, 2023 | 85.35% |
| Sep 30, 2023 | 88.30% |
| Jun 30, 2023 | 89.42% |
| Mar 31, 2023 | 90.98% |
| Dec 31, 2022 | 95.75% |
| Sep 30, 2022 | 86.03% |
| Jun 30, 2022 | 90.08% |
| Mar 31, 2022 | 92.24% |
| Dec 31, 2021 | 100.00% |